Arcutis to Host ZORYVE® (Roflumilast) Cream 0.15% FDA Approval Call With KOL Arcutis will host a KOL virtual event July 29, 2024

FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age Arcutis announced the FDA approval for ZORYVE (roflumilast) cream, 0.15%, for the treatment of atopic dermatitis

Arcutis Announces First Quarter 2024 Financial Results and Provides Business Update Arcutis today reported financial results for the quarter ended March 31, 2024, and provided a business update.

Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual Meeting Arcutis today announced five presentations at the 2024 American Academy of Dermatology (AAD) annual meeting.